XOMA Royalty Corp

XOMA Royalty Corp is a U.S.-based biotech royalty aggregator that acquires economic rights to future milestone payments, royalties, and commercial payments from partnered therapeutic programs. Its portfolio spans legacy out-licensing agreements, purchased royalty interests, and other income streams tied to drug development and product sales across multiple clinical and commercial assets.

60,8 %

+83,1 %

3.37

3.37

— XOMA Royalty Corp
%
Royalty and milestone interests60% Economic rights to future royalties, milestones, and commercial payments from partnered drug assets.
Purchased receivables25% Income from acquired receivables linked to royalty-bearing product sales and milestone events.
Licensing and collaboration revenue15% Upfront fees, annual license fees, and milestone payments from legacy out-licensing agreements.

XOMA Royalty does not sell medicines directly to patients; it monetizes contractual rights against biotech partners and...

  • Biotechnology license partnersprimary

    Companies that license legacy product candidates or platforms and pay upfront, annual, or milestone fees.

  • Pharmaceutical commercialization partnersprimary

    Drug developers and marketers whose product sales generate royalty income for XOMA.

  • Royalty financing counterpartiessecondary

    Sponsors of royalty transactions where XOMA acquires rights to future cash flows from therapeutic assets.

  • Clinical-stage drug developersprimary

    Partners advancing Phase 1-3 assets that can trigger milestone payments when development events occur.

XOMA Royalty is headquartered in the United States and its economic exposure is tied mainly to U.S...

  • •Headquartered in the United States
  • •Revenue depends on partner drug sales across multiple markets
  • •Clinical and regulatory milestones can arise in the U.S. and abroad
  • •Royalty exposure follows where partnered products are commercialized
  • •No disclosed country revenue split in the provided excerpts

XOMA Royalty’s strategy is to expand a diversified portfolio of royalty and milestone assets by acquiring rights to...

01
Expand the royalty portfolio through acquisitionsshort-term

More assets can diversify cash flow sources and reduce dependence on any single partner or program.

02
Focus on partnered clinical assets with high commercial potentialmedium-term

Early- to mid-stage programs can create large future milestone and royalty opportunities if development succeeds.

03
Maintain access to external capital for acquisitionsshort-term

The model is acquisition-driven and requires funding to buy new royalty and milestone rights.

XOMA Royalty’s cash generation depends on clinical progress, regulatory approvals, and product sales by third-party...

high

Partner development and commercialization risk

Milestones and royalties are only earned if third-party partners advance programs and sell products successfully.

Scope
Royalty and milestone portfolio
Materiality
high
high

Financing and liquidity risk

The company may need external capital to fund acquisitions and operating needs if cash generation is insufficient.

Scope
ATM programs and debt/equity markets
Materiality
high
medium

Valuation and forecast risk on royalty assets

Income recognition and asset values depend on estimated future royalties and milestone timing.

Scope
Purchased receivables and EIR/cost recovery assets
Materiality
high
medium

Macroeconomic and market volatility

Interest rates, equity market conditions, and broader economic stress can affect funding access and asset pricing.

Scope
U.S. and global capital markets
Materiality
medium
Revenue from contracts with customers
Can create lumpy quarterly revenue
Effective interest rate (EIR) method
Sensitive to forecast revisions
Cost recovery method
Affects timing of recognized income
Units-of-revenue amortization
Creates variability in reported revenue

Royalty Pharma plc

RPRX · Pharmaceutical Preparations

Xencor Inc

XNCR · Pharmaceutical Preparations

Xenetic Biosciences, Inc.

XBIO · Pharmaceutical Preparations

Xilio Therapeutics, Inc.

XLO · Pharmaceutical Preparations

Zymeworks Inc.

ZYME · Pharmaceutical Preparations

Olema Pharmaceuticals, Inc.

OLMA · Pharmaceutical Preparations

: 29/04/2026